Evidence map›Paper›PMID 25436122›Full record

ArticleJournal of gastrointestinal oncology2014

Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial.

Sidra Anwar, Wei Tan, Jinhee Yu, Alan Hutson, Milind Javle, Renuka Iyer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. A Structural Model of Quality of Life in Patients after Colorectal Cancer Surgery.International journal of environmental research and public health · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Sexual health and needs for sexology care in digestive cancer patients undergoing chemotherapy: a 4-month cross-sectional study in a French University Hospital.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sidra Anwar1 Department of Internal Medicine, State University of New York, Buffalo NY, USA ; 2 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USA ; 3 Department of Biostatistics, State University of New York, Buffalo NY, USA ; 4 Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USA ; 5 Department of Medicine, Roswell Park Cancer Institute, Buffalo NY, USA.
Wei Tan1 Department of Internal Medicine, State University of New York, Buffalo NY, USA ; 2 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USA ; 3 Department of Biostatistics, State University of New York, Buffalo NY, USA ; 4 Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USA ; 5 Department of Medicine, Roswell Park Cancer Institute, Buffalo NY, USA.
Jinhee Yu1 Department of Internal Medicine, State University of New York, Buffalo NY, USA ; 2 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USA ; 3 Department of Biostatistics, State University of New York, Buffalo NY, USA ; 4 Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USA ; 5 Department of Medicine, Roswell Park Cancer Institute, Buffalo NY, USA.
Alan Hutson1 Department of Internal Medicine, State University of New York, Buffalo NY, USA ; 2 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USA ; 3 Department of Biostatistics, State University of New York, Buffalo NY, USA ; 4 Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USA ; 5 Department of Medicine, Roswell Park Cancer Institute, Buffalo NY, USA.
Milind Javle1 Department of Internal Medicine, State University of New York, Buffalo NY, USA ; 2 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USA ; 3 Department of Biostatistics, State University of New York, Buffalo NY, USA ; 4 Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USA ; 5 Department of Medicine, Roswell Park Cancer Institute, Buffalo NY, USA.
Renuka Iyer1 Department of Internal Medicine, State University of New York, Buffalo NY, USA ; 2 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USA ; 3 Department of Biostatistics, State University of New York, Buffalo NY, USA ; 4 Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USA ; 5 Department of Medicine, Roswell Park Cancer Institute, Buffalo NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePancreatic cancer is rapidly fatal with median survival of only 6 months (mo). Quality-of-life (QoL) was analyzed prospectively in a phase 2 study of gemcitabine (G), capecitabine (C) and bevacizumab (B) in APC patients.

methodsA total of 50 patients with APC received B 15 mg/kg, C 1,300 mg/m(2) daily for 2 weeks and G 1,000 mg/m(2) weekly 2 times; cycles were repeated every 21 days. ENDPOINTS: progression free survival (PFS), overall survival (OS) and assessment of QoL prior to each cycle using the European organization for research and treatment of cancer (EORTC) PAN-26 QoL questionnaire. An exact 95% confidence interval (CI) (Clopper-Pearson method) was used to assess rate of improved QoL (defined as >5% decrease in two consecutive scores compared with baseline).

resultsPatient characteristics- Stage IIB/III/IV: 3/5/42; Sex: 28 M/22 F; Median age: 64 years. QoL in patients- improved: 56%, no improvement: 24%; unevaluable: 20%. Median PFS: 5.8 mo, OS: 9.8 mo. QoL improvement rate: 28/40=0.7 (95% CI: 0.53-0.83) in evaluable patients. Using QoL improvement rate, no significant difference was seen in patients with OS ≥6 mo compared to OS <6 mo. However QoL scores at 3 and 6 weeks from start of treatment correlated strongly with ≥6 mo survival (P value 0.0092 and 0.0081, respectively).

conclusionsBaseline score and change in QoL scores of patients on G, C and B were not predictive of survival ≥6 mo. Post treatment scores at 3 and 6 weeks from start of therapy however, were predictive of survival ≥6 mo suggesting the potential predictive value of this tool for use in future studies.

Indexed as

biomarkersneoplasm, European organization for research and treatment of cancer (EORTC)outcomespalliative carepancreaspancreatic cancerQuality of life (QoL)supportive oncology

Identifiers

PMID25436122
PMCPMC4226818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.